TY - JOUR
T1 - Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients
AU - Okba, Nisreen M A
AU - Müller, Marcel A
AU - Li, Wentao
AU - Wang, Chunyan
AU - GeurtsvanKessel, Corine H
AU - Corman, Victor M
AU - Lamers, Mart M
AU - Sikkema, Reina S
AU - de Bruin, Erwin
AU - Chandler, Felicity D
AU - Yazdanpanah, Yazdan
AU - Le Hingrat, Quentin
AU - Descamps, Diane
AU - Houhou-Fidouh, Nadhira
AU - Reusken, Chantal B E M
AU - Bosch, Berend-Jan
AU - Drosten, Christian
AU - Koopmans, Marion P G
AU - Haagmans, Bart L
PY - 2020/7
Y1 - 2020/7
N2 - A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.
AB - A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.
U2 - 10.3201/eid2607.200841
DO - 10.3201/eid2607.200841
M3 - Article
C2 - 32267220
SN - 1080-6040
VL - 26
SP - 1478
EP - 1488
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 7
ER -
